1.    The controlled substances listed in this section are included in schedule III.

Ask a criminal law question, get an answer ASAP!
Click here to chat with a criminal defense lawyer and protect your rights.

2.    Schedule III consists of the drugs and other substances, by whatever official name, common or usual name, chemical name, or brand name designated, listed in this section.

3.    Stimulants. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers (whether optical, position, or geometric), and salts of such isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:

a.    Those compounds, mixtures, or preparations in dosage unit form containing any stimulant substances listed in schedule II and any other drug of the quantitative composition shown in that schedule for those drugs or which is the same except that it contains a lesser quantity of controlled substances. b.    Benzphetamine.

c.    Chlorphentermine. d.    Clortermine.

e.    Phendimetrazine.

4.    Depressants. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation that contains any quantity of the following substances having a depressant effect on the central nervous system:

a.    Any compound, mixture, or preparation containing: (1) Amobarbital; (2) Secobarbital; (3) Pentobarbital; or any salt thereof and one or more other active medicinal ingredients which are not listed in any schedule.

b.    Any suppository dosage form containing: (1) Amobarbital; (2) Secobarbital; (3) Pentobarbital; or any salt of any of these drugs and approved by the food and drug administration for marketing only as a suppository.

c.    Any substance that contains any quantity of a derivative of barbituric acid, or any salt of a derivative of barbituric acid, except those substances which are specifically listed in other schedules thereof. d.    Chlorhexadol.

e.    Embutramide.

f.    Gamma-hydroxybutyric acid in a United States food and drug administration- approved drug product.

g.    Ketamine.

h.    Lysergic acid.

i.    Lysergic acid amide. j.    Methyprylon.

k.    Perampanel.

l.    Sativex or its successor name as determined by the federal food and drug administration.

m.    Sulfondiethylmethane. n.    Sulfonethylmethane.

o.    Sulfonmethane.

p.    Tiletamine and zolazepam or any salt thereof. Some trade or other names for a tiletamine-zolazepam combination product: Telazol. Some trade or other names for tiletamine: 2-(ethylamino)-2-(2-thienyl)-cyclohexanone. Some trade or other names for zolazepam: 4-2(2-fluorophenyl)-6, 8-dihydro-1,3,8-trimethylpyrazolo- [3,4-e][1,4]-diazepin-7(1H)-one, flupyrazapon.

5.    Nalorphine.

6.    Narcotic drugs. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation that contains any of the following narcotic drugs, or their salts calculated as the free anhydrous base or alkaloid, in limited quantities as set forth below:

a.     (1) Not more than 1.80 grams of codeine per 100 milliliters or not more than 90 milligrams per dosage unit, with an equal or greater quantity of an isoquinoline alkaloid of opium.

(2) Not more than 1.80 grams of codeine per 100 milliliters or not more than 90 milligrams per dosage unit, with one or more active, non-narcotic ingredients in recognized therapeutic amounts.

(3) Not more than 1.80 grams of dihydrocodeine per 100 milliliters or not more than 90 milligrams per dosage unit, with one or more active, non-narcotic ingredients in recognized therapeutic amounts.

(4) Not more than 300 milligrams of ethylmorphine per 100 milliliters or not more than 15 milligrams per dosage unit, with one or more active, non-narcotic ingredients in recognized therapeutic amounts.

(5) Not more than 500 milligrams of opium per 100 milliliters or per 100 grams, or not more than 25 milligrams per dosage unit, with one or more active, non-narcotic ingredients in recognized therapeutic amounts.

(6) Not more than 50 milligrams of morphine per 100 milliliters or per 100 grams with one or more active, non-narcotic ingredients in recognized therapeutic amounts.

b.    Buprenorphine.

7.    Anabolic steroids. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation that contains any of the following anabolic steroids:

a.    3beta,17-dihydroxy-5a-androstane; b.    3alpha,17beta-dihydroxy-5a-androstane; c.    5alpha-androstan-3,17-dione; d.    1-androstenediol (3beta,17beta-dihydroxy-5alpha-androst-1-ene); e.    1-androstenediol (3alpha,17beta-dihydroxy-5alpha-androst-1-ene); f.    4-androstenediol (3beta,17beta-dihydroxy-4-ene); g.    5-androstenediol (3beta,17beta-dihydroxy-androst-5-ene); h.    1-androstenedione ([5alpha]-androst-1-en-3,17-dione); i.    4-androstenedione (androst-4-en-3,17-dione); j.    5-androstenedione (androst-5-en-3,17-dione); k.    Bolasterone (7alpha,17alpha-dimethyl-17beta-hydroxyandrost-4-en-3-one); l.    Boldenone (17beta-hydroxyandrost-1,4,-diene-3-one); m.    Boldione (androsta-1,4-diene-3,17-dione); n.    Calusterone (7beta,17alpha-dimethyl-17beta-hydroxyandrost-4-en-3-one); o.    Clostebol (4-chloro-17beta-hydroxyandrost-4-en-3-one); p. Dehydrochloromethyltestosterone     (4-chloro-17beta-hydroxy-17alpha-methyl- androst-1,4-dien-3-one); q.    Delta-1-dihydrotestosterone (also known as ‘1-testosterone’) (17beta-hydroxy- 5alpha-androst-1-en-3-one); r. Desoxymethyltestosterone (17a-methyl-5a-androst-2-en-17ol) (also known as madol); s.    4-dihydrotestosterone (17beta-hydroxy-androstan-3-one); t.    Drostanolone (17beta-hydroxy-2alpha-methyl-5alpha-androstan-3-one); u.    Ethylestrenol (17alpha-ethyl-17beta-hydroxyestr-4-ene);    v.    Fluoxymesterone (9-fluoro-17alpha-methyl-11beta, 17beta-dihydroxyandrost-4- en-3-one); w.    Formebolone (2-formyl-17alpha-methyl-11alpha, 17beta-dihydroxyandrost-1,4- dien-3-one); x.    Furazabol (17alpha-methyl-17beta-hydroxyandrostano[2,3-c]-furazan); y.    13beta-ethyl-17alpha-hydroxygon-4-en-3-one; z.    4-hydroxytestosterone (4,17beta-dihydroxy-androst-4-en-3-one); aa.    4-hydroxy-19-nortestosterone (4,17beta-dihydroxy-estr-4-en-3-one); bb.    Mestanolone (17alpha-methyl-17beta-hydroxy-5-androstan-3-one); cc.    Mesterolone (1alpha-methyl-17beta-hydroxy-[5alpha]-androstan-3-one); dd.    Methandienone (17alpha-methyl-17beta-dihydroxyandrost-1,4-dien-3-one); ee.    Methandriol (17alpha-methyl-3beta,17beta-dihydroxyandrost-5-ene); ff.    Methasterone (2[alpha],17[alpha]-dimethyl-5[alpha]-androstan-17[beta]-ol-3-one); gg.    Methenolone (1-methyl-17beta-hydroxy-5alpha-androst-1-en-3-one); hh.    17alpha-methyl-3beta,17beta-dihydroxy-5a-androstane; ii.    17alpha-methyl-3alpha,17beta-dihydroxy-5a-androstane; jj.    17alpha-methyl-3beta,17beta-dihyroxyandrost-4-ene; kk.    17alpha-methyl-4-hydroxynandrolone             (17alpha-methyl-4-hydroxy-17beta- hydroxyestr-4-en-3-one); ll.    Methyldienolone (17alpha-methyl-17beta-hydroxyestra-4,9(10)-dien-3-one); mm.    Methyltrienolone (17alpha-methyl-17beta-hydroxyestra-4,9(11)-trien-3-one); nn.    Methyltestosterone (17alpha-methyl-17beta-hydroxyandrost-4-en-3-one); oo.    Mibolerone (7alpha,17alpha-dimethyl-17beta-hydroxyestr-4-en-3-one); pp.    17alpha-methyl-delta1-dihydrotestosterone     (17bbeta-hydroxy-17alpha-methyl- 5alpha-androst-1-en-3-one) (also known as ’17-alpha-methyl-1-testosterone’); qq.    Nandrolone (17beta-hydroxyestr-4-en-3-one); rr.    19-nor-4-androstenediol (3beta,17beta-dihydroxyestr-4-ene); ss.    19-nor-4-androstenediol (3alpha,17beta-dihydroxyestr-4-ene); tt.    19-nor-5-androstenediol (3beta,17beta-dihydroxyestr-5-ene); uu.    19-nor-5-androstenediol (3alpha,17-beta-dihydroxyester-5-ene); vv.    19-nor-4-androstenedione (estr-4-en-3,17-dione); ww.    19-nor-4,9(10)-androstadienedione (estra-4,9(10)-diene-3,17-dione); xx.    19-nor-5-androstenedione (estr-5-en-3,17-dione); yy.    Norboletheone (13beta,17alpha-diethyl-17beta-hydroxygon-4-en-3-one); zz.    Norclostebol (4-chloro-17beta-hydroxyestr-4-en-3-one); aaa.    Norethandrolone (17alpha-ethyl-17beta-hydroxyestr-4-en-3-one); bbb.    Normethandrolone (17alpha-methyl-17beta-hydroxyestr-4-en-3-one); ccc.    Oxandrolone (17alpha-methyl-17beta-hydroxy-2-oxa-[5alpha]-androstan-3-one); ddd.    Oxymesterone (17alpha-methyl-4-17beta-dihydroxyandrost-4-en-3-one); eee.    Oxymetholone (17alpha-methyl-2-hydroxymethylene-17beta-hydroxy [5alpha]- androstan-3-one); fff.    Stanozolol             (17alpha-methyl-17beta-hydroxy[5alpha]-androst-2-eno[3,2-c]- pyrazole); ggg.    Stenbolone (17beta-hydroxy-2-methyl-[5alpha]-androst-1-en-3-one); hhh.    Prostanozol (17[beta]- hydroxy-5[alpha]-androstano[3,2-c]pyrazole); iii.    Testolactone     (13-hydroxy-3-oxo-13,17-secoandrosta-1,4-dien-17-oic     acid lactone); jjj.    Testosterone (17beta-hydroxyandrost-4-en-3-one); kkk.    Tetrahydrogestrinone (13beta,17alpha-diethyl-17beta-hydroxygon-4,9,11-trien-3- one); lll.    Trenbolone (17beta-hydroxyestr-4,9,11-trien-3-one); or any salt, ester, or isomer of a drug or substance described or listed in this subsection, if that salt, ester, or isomer promotes muscle growth.

The term does not include an anabolic steroid that is expressly intended for administration through implants to cattle or other nonhuman species and which has been approved by the secretary of health and human services for administration    unless any person prescribes, dispenses, possesses, delivers, or distributes for human use.

8.    Hallucinogenic substances.

a.    Dronabinol (synthetic) [(-)-delta-9-(trans)-tetrahydrocannabinol] in sesame oil and encapsulated in a soft gelatin capsule in a United States food and drug administration-approved drug product.

b.    Any product in hard or soft gelatin capsule form containing natural dronabinol (derived from the cannabis plant) or synthetic dronabinol (produced from synthetic materials) in sesame oil, for which an abbreviated new drug application has been approved by the food and drug administration under section 505(j) of the Federal Food, Drug, and Cosmetic Act [21 U.S.C. § 355(j)] which references as its listed drug the drug product referred to in subdivision a.

9.    The board may except by rule any compound, mixture, or preparation containing any stimulant or depressant substance listed in subsections 3 and 4 from the application of all or any part of this chapter if the compound, mixture, or preparation contains one or more active medicinal ingredients not having a stimulant or depressant effect on the central nervous system, and if the admixtures are included therein in combinations, quantity, proportion, or concentration that vitiate the potential for abuse of the substances which have a stimulant or depressant effect on the central nervous system.